美国 · 平台与数据 · Stocktwits

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

来源：Stocktwits · 美国 8 小时前

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.

在 Stocktwits 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (stocktwits.com)

推荐阅读

Verra Mobility (NASDAQ:VRRM) Hits New 1-Year Low - Should You Sell?

The Motley Fool

Cavco (CVCO) Q2 2027 Earnings Call Transcript

Crude oil jumps as Iran says four tankers struck mines in the Strait of Hormuz

Wall Street closes sharply lower as AI cash burn fears spark tech selloff

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

CNBC is at the Fort Lauderdale International Boat Show